ESMO guideline express update for epithelial ovarian cancer adds rucaparib as a first-line PARP inhibitor maintenance option and recommends MIRV for recurrent, high FRα disease after 1-3 prior therapies with a platinum-free interval under 6 months.
Guideline
González-Martín et al. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer